Company Profile


Company Overview

Certara is a growing company that provides a novel and exciting place to work. Our purpose is to assist in accelerating the development of meaningful medicines that make an impact on our society and the people that need them most. Innovation and creativity are highly valued, and everyone is given the opportunity for training and continuous development. Our portfolio spans the discovery, preclinical, clinical and post-marketing phases of drug development, working with 1,200 commercial companies, 250 academic institutions, and numerous regulatory agencies.

Certara Strategic Consulting (CSC) is a division of Certara and is the largest and most comprehensive model-informed drug development and strategic pharmacometrics organization. CSC delivers value by integrating advanced modeling and simulation approaches into the most crucial drug development deliverables—to inform internal decision-making and strengthen global regulatory submissions. Leveraging our experience working on thousands of key drug development projects on behalf of hundreds of biopharma companies, CSC brings its track record of success and a broad range of expertise to each assignment.

Company History

Certara was formed in 2008 by the merger of Tripos®International, the leading provider of drug discovery informatics products and services, with the Pharsight® Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development. In 2012, the ability to provide innovation solutions to the pharmaceutical industry was further augmented with the acquisition of Simcyp® Limited, the leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations. The following year, the acquisition of Great Lakes Drug Development, Inc further increased the depth of Certara’s early drug development analysis, and modeling and simulation capabilities.

Seeking to add global regulatory writing and submission services to Certara’s drug development consulting expertise, the addition of Synchrogenix® occurred in 2014. In early 2015, Certara’s regulatory and medical writing consultancy, Synchrogenix, acquired ClinGenuityTM, the only artificial intelligence-assisted medical writing service in the pharmaceutical industry. Later that year, Certara created the preeminent global strategic modeling and simulation consultancy through the merger of its consulting group, Pharsight Consulting Services, with Quantitative SolutionsTM, an international pharmacometrics consulting company. At the end of 2015, Certara created a division within Simcyp focused on Quantitative Systems Pharmacology through the acquisition of XenologiQ, led by Dr. Piet van der Graaf. In September, 2016, the company expanded its consulting footprint through the acquisition of d3 Medicine, a global organization focused on strategic planning and stewardship of complex drug development programs.

Through the years, Certara has evolved and continues to grow to provide our clients with solutions, spanning the discovery, preclinical and clinical stages of drug development, that enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety.


The wellbeing of our employees is a priority at Certara, and that is why we support the most important aspects of their lives:

Financial - competitive pay, incentives, retirement plans, income security programs
Health & Wellness - comprehensive benefits, wellness programs, office environment focused on health lifestyles
Work/Life - generous paid time off, employee assistance program, flexible work arrangements
Growth & Development - performance driven environment including training, seminars, mobility and transfer opportunities
Community Impact - volunteering, matching gifts, charitable contributions

Positions Available
This company currently has no jobs posted.

Click here to search for jobs.